Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer

Table 3 Mutational analysis of KRAS (Codon 12 and 13), DPC-4, and BRCA-2 gene mutations within pancreatic cancer subjects

Key genes in PC patients evaluated for mutational analysis	Mutation’s present	Mutation’s absent	P value for mutations present vs absent
KRAS mutation (codon 12)	16	34	0.05
KRAS mutation (codon 13)	12	38	0.05
DPC-4 mutation (1203G>T)	0	50	0.001
BRCA-2 mutation (6174delT)	0	50	0.001

KRAS: Kirsten rat sarcoma; DPC-4: Deleted in pancreatic cancer-4; BRCA-2: Breast cancer type 2.